VOR BIOPHARMA INC (VOR) Fundamental Analysis & Valuation
NASDAQ:VOR • US9290332074
Current stock price
14.15 USD
+0.34 (+2.46%)
Last:
This VOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VOR Profitability Analysis
1.1 Basic Checks
- In the past year VOR has reported negative net income.
- VOR had a negative operating cash flow in the past year.
- In the past 5 years VOR always reported negative net income.
- VOR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- VOR's Return On Assets of -149.96% is on the low side compared to the rest of the industry. VOR is outperformed by 84.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.96% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-97.09%
ROA(5y)-70.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VOR Health Analysis
2.1 Basic Checks
- The number of shares outstanding for VOR has been increased compared to 1 year ago.
- VOR has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -4.36, we must say that VOR is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -4.36, VOR is not doing good in the industry: 61.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- VOR has a Current Ratio of 18.20. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
- VOR has a Current ratio of 18.20. This is amongst the best in the industry. VOR outperforms 93.98% of its industry peers.
- A Quick Ratio of 18.20 indicates that VOR has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 18.20, VOR belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.2 | ||
| Quick Ratio | 18.2 |
3. VOR Growth Analysis
3.1 Past
- VOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.09%, which is quite impressive.
EPS 1Y (TTM)22.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%393.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, VOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.03% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.73%
EPS Next 2Y35.5%
EPS Next 3Y21.55%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. VOR Valuation Analysis
4.1 Price/Earnings Ratio
- VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VOR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as VOR's earnings are expected to grow with 21.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.5%
EPS Next 3Y21.55%
5. VOR Dividend Analysis
5.1 Amount
- No dividends for VOR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VOR Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:VOR (4/27/2026, 11:18:04 AM)
14.15
+0.34 (+2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30 2026-03-30/bmo
Earnings (Next)05-12 2026-05-12
Inst Owners58.78%
Inst Owner Change0.05%
Ins Owners0.01%
Ins Owner Change-17.22%
Market Cap691.23M
Revenue(TTM)N/A
Net Income(TTM)-695.98M
Analysts84.62
Price Target38.38 (171.24%)
Short Float %12.92%
Short Ratio5.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)811.97%
Min EPS beat(2)-1.38%
Max EPS beat(2)1625.33%
EPS beat(4)1
Avg EPS beat(4)304.18%
Min EPS beat(4)-394.6%
Max EPS beat(4)1625.33%
EPS beat(8)3
Avg EPS beat(8)143.85%
EPS beat(12)4
Avg EPS beat(12)96.37%
EPS beat(16)6
Avg EPS beat(16)72.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.69%
PT rev (3m)3.37%
EPS NQ rev (1m)29.42%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)21.75%
EPS NY rev (3m)25.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-26.49
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.92
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -149.96% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-97.09%
ROA(5y)-70.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.59% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.2 | ||
| Quick Ratio | 18.2 | ||
| Altman-Z | -4.36 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)23.23%
Cap/Depr(5y)135.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%393.64%
EPS Next Y83.73%
EPS Next 2Y35.5%
EPS Next 3Y21.55%
EPS Next 5Y15.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-206.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.66%
EBIT Next 3Y9.28%
EBIT Next 5YN/A
FCF growth 1Y-43.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.2%
OCF growth 3YN/A
OCF growth 5YN/A
VOR BIOPHARMA INC / VOR Fundamental Analysis FAQ
What is the fundamental rating for VOR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VOR.
What is the valuation status for VOR stock?
ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.
What is the profitability of VOR stock?
VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.
What is the expected EPS growth for VOR BIOPHARMA INC (VOR) stock?
The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to grow by 83.73% in the next year.